CVS 87.50 CVS Corp $CVS Hit a 52 week high of 87.88 Closing the day 11/05/14 at 87.50 +2.03 +2.38% With a day low of 85.68 and a total volume of 5,460,724.
CVS Recent Posts: http://investorshangout.com/CVS-Caremark-Corp-CVS-50666/
CVS CVS Corp Recent Headline News
Monotype Gets Its Font Tech Deeper Into Advertising
at Investor's Business Daily - Wed Nov 05, 5:26PM CST
Monotype Imaging Holdings (TYPE), a leading provider of typefaces and typeface technology, has been on a mission to beauty websites with new and better-rendered fonts. Now the Woburn, Mass.-based company is looking to make digital advertising more...
EBAY: 53.58 (+0.31), PFE: 30.04 (-0.24), CVS: 87.50 (+2.03), COST: 136.50 (-0.05), ADBE: 71.37 (+0.30), TYPE: 28.36 (+0.25)
CVS Caremark Rises 2.38% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Wed Nov 05, 3:56PM CST
CVS Caremark (NYSE:CVS) traded in a range yesterday that spanned from a low of $85.68 to a high of $87.88. Yesterday, the shares gained 2.4%, which took the trading range above the 3-day high of $87.16 on volume of 5.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CVS: 87.50 (+2.03)
Services Stocks On The Rise With Help From 3 Stocks
at The Street - Wed Nov 05, 11:25AM CST
TheStreet highlights 3 stocks pushing the services sector higher today.
V: 249.53 (+6.56), FOX: 33.41 (+1.42), CVS: 87.50 (+2.03)
CVS Health Delivers a Broadly Solid Third Quarter
Andrés Cardenal, The Motley Fool - Motley Fool - Tue Nov 04, 2:44PM CST
Source: CVS Health On Tuesday, CVS Health delivered strong results for the third quarter of 2014. While the numbers were not particularly explosive in comparison to expectations, performance was solid across the board. Let's take a look at the...
CVS: 87.50 (+2.03)
CVS Health Beats Q3 Earnings, Revenues; Narrows Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 1:00PM CST
CVS Health Corporation (CVS) ??? formerly known as CVS Caremark ??? reported third-quarter 2014 adjusted earnings per share (EPS) of $1.15.
BSX: 13.33 (+0.07), ICUI: 71.85 (+0.71), ABAX: 54.45 (+1.07), CVS: 87.50 (+2.03)
CVS Health (CVS) Earnings Report: Q3 2014 Conference Call Transcript
at The Street - Tue Nov 04, 12:26PM CST
The following CVS Health (CVS) conference call took place on November 4, 2014, 08:30 AM ET. This is a transcript of that earnings call:
CVS: 87.50 (+2.03)
CVS Q3 Earnings, Sales Top Despite Banning Tobacco
at Investor's Business Daily - Tue Nov 04, 12:21PM CST
CVS Health was cautious with its fourth-quarter earnings guidance after reporting view-topping results for Q3 that were slightly impacted by last month's announced tobacco ban. CVS Health's (CVS) earnings rose 9.5% to $1.15, topping by 2 cents, and...
CVS: 87.50 (+2.03), AAPL: 108.86 (+0.26), WAG: 65.66 (+0.42), RAD: 5.19 (-0.07)
CVS Health (CVS) Stock Is Falling Following Decline in Third Quarter Net Profit
at The Street - Tue Nov 04, 12:20PM CST
CVS Health (CVS) shares are dropping despite its third quarter earnings beat due to a drop in third quarter profits.
CVS: 87.50 (+2.03)
CVS's 3Q benefits from generics, specialty drugs
AP - Tue Nov 04, 10:29AM CST
WOONSOCKET, R.I. (AP) — CVS Health Corp. reported better-than-expected third-quarter earnings Tuesday as increased use of specialty drugs helped offset missing sales of tobacco products, which the company stopped selling this fall.
CVS: 87.50 (+2.03)
CVS Caremark (CVS) Crosses Pivot Point Support at $85.79
Comtex SmarTrend(R) - Tue Nov 04, 10:14AM CST
CVS Caremark (NYSE:CVS) has opened bearishly below the pivot of $86.24 today and has reached the first level of support at $85.79. Should the shares continue to fall, the support pivots of $85.47 and $84.70 will be of interest.
CVS: 87.50 (+2.03)
What We Now Know 3/4 Thru Q3 Earnings Season - Ahead of Wall Street
Sheraz Mian - Zacks Investment Research - Tue Nov 04, 8:53AM CST
With not much on the domestic economic calendar, headlines about lowered European growth outlook and a slew of earnings reports provide the backdrop for today's trading action.
CVS: 87.50 (+2.03), KORS: 72.40 (+0.98), BABA: 108.67 (+2.60)
CVS Health Reports Third Quarter Results
PR Newswire - Tue Nov 04, 6:00AM CST
CVS Health Corporation (NYSE: CVS) today announced operating results for the three months ended September 30, 2014.
CVS: 87.50 (+2.03)
Will CVS Health (CVS) Keep its Earnings Streak Alive in Q3? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 2:30PM CST
CVS Health Corporation (CVS) is scheduled to report its third-quarter 2014 results before the opening bell on Nov 4.
AMSG: 51.37 (-0.91), CFN: 57.41 (+0.03), CVS: 87.50 (+2.03), HSIC: 122.21 (+1.37)
Must-See Charts on How to Trade CVS Health After End to Tobacco Sales
at The Street - Mon Nov 03, 12:47PM CST
Check out these must-see charts on CVS Health after the drug store chain successfully quit selling smokes and expanded its Minute Clinics.
SPY: 202.34 (+1.27), CVS: 87.50 (+2.03), WAG: 65.66 (+0.42), HUM: 138.94 (+1.19)
The Herrick Company Announces $50-Million Sale of CVS Caremark Properties Located Throughout the U.S.
PR Newswire - Mon Nov 03, 11:45AM CST
Norton Herrick, Chairman of The Herrick Company, Inc. (the Company), one of the nation's leading real estate investment firms, today announced that affiliates of the Company have recently sold pharmacy/retail properties located throughout the U.S. The properties, all of which are occupied under long-term triple net leases with CVS Caremark, were sold for approximately $50 million.
CVS: 87.50 (+2.03)
CVS Health (CVS) Stock Up Ahead of Earnings Report
at The Street - Mon Nov 03, 10:24AM CST
CVS Health (CVS) is gaining ahead of its third-quarter earnings report scheduled for release before the market opens on Tuesday.
CVS: 87.50 (+2.03)
Upcoming Earnings, Financial Results, New Affiliations, and Study Results - Research Reports on Regeneron, Valeant, CVS Health, CIGNA and Baxter
PR Newswire - Mon Nov 03, 8:15AM CST
Today, Analysts Review released its research reports regarding Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), Valeant Pharmaceuticals Intl Inc. (NYSE: VRX), CVS Health Corp. (NYSE: CVS), CIGNA Corporation (NYSE: CI) and Baxter International Inc. (NYSE: BAX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7653-100free.
CI: 100.00 (-1.02), VRX: 131.91 (-1.70), BAX: 70.90 (+2.45), CVS: 87.50 (+2.03), REGN: 368.51 (-3.88)
CVS Health Announces $10 Million Commitment to Stand Up To Cancer to Fund Innovative Cancer Research
PR Newswire - Mon Nov 03, 8:00AM CST
CVS/pharmacy, the retail division of CVS Health (NYSE: CVS), today announced an in-store fundraising campaign to help raise funds to support cancer research. Now through November 22, CVS/pharmacy customers will have the opportunity to support Stand Up To Cancer (SU2C) at the register in stores nationwide and online at www.cvs.com/SU2C. SU2C raises funds to accelerate the pace of cancer research to get new therapies to patients quickly and save lives. This campaign is part of CVS Health's three-year $10 million commitment to SU2C.
CVS: 87.50 (+2.03)
CVS Recent Posts: http://investorshangout.com/CVS-Caremark-Corp-CVS-50666/
CVS CVS Corp Recent Headline News
Monotype Gets Its Font Tech Deeper Into Advertising
at Investor's Business Daily - Wed Nov 05, 5:26PM CST
Monotype Imaging Holdings (TYPE), a leading provider of typefaces and typeface technology, has been on a mission to beauty websites with new and better-rendered fonts. Now the Woburn, Mass.-based company is looking to make digital advertising more...
EBAY: 53.58 (+0.31), PFE: 30.04 (-0.24), CVS: 87.50 (+2.03), COST: 136.50 (-0.05), ADBE: 71.37 (+0.30), TYPE: 28.36 (+0.25)
CVS Caremark Rises 2.38% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Wed Nov 05, 3:56PM CST
CVS Caremark (NYSE:CVS) traded in a range yesterday that spanned from a low of $85.68 to a high of $87.88. Yesterday, the shares gained 2.4%, which took the trading range above the 3-day high of $87.16 on volume of 5.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CVS: 87.50 (+2.03)
Services Stocks On The Rise With Help From 3 Stocks
at The Street - Wed Nov 05, 11:25AM CST
TheStreet highlights 3 stocks pushing the services sector higher today.
V: 249.53 (+6.56), FOX: 33.41 (+1.42), CVS: 87.50 (+2.03)
CVS Health Delivers a Broadly Solid Third Quarter
Andrés Cardenal, The Motley Fool - Motley Fool - Tue Nov 04, 2:44PM CST
Source: CVS Health On Tuesday, CVS Health delivered strong results for the third quarter of 2014. While the numbers were not particularly explosive in comparison to expectations, performance was solid across the board. Let's take a look at the...
CVS: 87.50 (+2.03)
CVS Health Beats Q3 Earnings, Revenues; Narrows Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 1:00PM CST
CVS Health Corporation (CVS) ??? formerly known as CVS Caremark ??? reported third-quarter 2014 adjusted earnings per share (EPS) of $1.15.
BSX: 13.33 (+0.07), ICUI: 71.85 (+0.71), ABAX: 54.45 (+1.07), CVS: 87.50 (+2.03)
CVS Health (CVS) Earnings Report: Q3 2014 Conference Call Transcript
at The Street - Tue Nov 04, 12:26PM CST
The following CVS Health (CVS) conference call took place on November 4, 2014, 08:30 AM ET. This is a transcript of that earnings call:
CVS: 87.50 (+2.03)
CVS Q3 Earnings, Sales Top Despite Banning Tobacco
at Investor's Business Daily - Tue Nov 04, 12:21PM CST
CVS Health was cautious with its fourth-quarter earnings guidance after reporting view-topping results for Q3 that were slightly impacted by last month's announced tobacco ban. CVS Health's (CVS) earnings rose 9.5% to $1.15, topping by 2 cents, and...
CVS: 87.50 (+2.03), AAPL: 108.86 (+0.26), WAG: 65.66 (+0.42), RAD: 5.19 (-0.07)
CVS Health (CVS) Stock Is Falling Following Decline in Third Quarter Net Profit
at The Street - Tue Nov 04, 12:20PM CST
CVS Health (CVS) shares are dropping despite its third quarter earnings beat due to a drop in third quarter profits.
CVS: 87.50 (+2.03)
CVS's 3Q benefits from generics, specialty drugs
AP - Tue Nov 04, 10:29AM CST
WOONSOCKET, R.I. (AP) — CVS Health Corp. reported better-than-expected third-quarter earnings Tuesday as increased use of specialty drugs helped offset missing sales of tobacco products, which the company stopped selling this fall.
CVS: 87.50 (+2.03)
CVS Caremark (CVS) Crosses Pivot Point Support at $85.79
Comtex SmarTrend(R) - Tue Nov 04, 10:14AM CST
CVS Caremark (NYSE:CVS) has opened bearishly below the pivot of $86.24 today and has reached the first level of support at $85.79. Should the shares continue to fall, the support pivots of $85.47 and $84.70 will be of interest.
CVS: 87.50 (+2.03)
What We Now Know 3/4 Thru Q3 Earnings Season - Ahead of Wall Street
Sheraz Mian - Zacks Investment Research - Tue Nov 04, 8:53AM CST
With not much on the domestic economic calendar, headlines about lowered European growth outlook and a slew of earnings reports provide the backdrop for today's trading action.
CVS: 87.50 (+2.03), KORS: 72.40 (+0.98), BABA: 108.67 (+2.60)
CVS Health Reports Third Quarter Results
PR Newswire - Tue Nov 04, 6:00AM CST
CVS Health Corporation (NYSE: CVS) today announced operating results for the three months ended September 30, 2014.
CVS: 87.50 (+2.03)
Will CVS Health (CVS) Keep its Earnings Streak Alive in Q3? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 2:30PM CST
CVS Health Corporation (CVS) is scheduled to report its third-quarter 2014 results before the opening bell on Nov 4.
AMSG: 51.37 (-0.91), CFN: 57.41 (+0.03), CVS: 87.50 (+2.03), HSIC: 122.21 (+1.37)
Must-See Charts on How to Trade CVS Health After End to Tobacco Sales
at The Street - Mon Nov 03, 12:47PM CST
Check out these must-see charts on CVS Health after the drug store chain successfully quit selling smokes and expanded its Minute Clinics.
SPY: 202.34 (+1.27), CVS: 87.50 (+2.03), WAG: 65.66 (+0.42), HUM: 138.94 (+1.19)
The Herrick Company Announces $50-Million Sale of CVS Caremark Properties Located Throughout the U.S.
PR Newswire - Mon Nov 03, 11:45AM CST
Norton Herrick, Chairman of The Herrick Company, Inc. (the Company), one of the nation's leading real estate investment firms, today announced that affiliates of the Company have recently sold pharmacy/retail properties located throughout the U.S. The properties, all of which are occupied under long-term triple net leases with CVS Caremark, were sold for approximately $50 million.
CVS: 87.50 (+2.03)
CVS Health (CVS) Stock Up Ahead of Earnings Report
at The Street - Mon Nov 03, 10:24AM CST
CVS Health (CVS) is gaining ahead of its third-quarter earnings report scheduled for release before the market opens on Tuesday.
CVS: 87.50 (+2.03)
Upcoming Earnings, Financial Results, New Affiliations, and Study Results - Research Reports on Regeneron, Valeant, CVS Health, CIGNA and Baxter
PR Newswire - Mon Nov 03, 8:15AM CST
Today, Analysts Review released its research reports regarding Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), Valeant Pharmaceuticals Intl Inc. (NYSE: VRX), CVS Health Corp. (NYSE: CVS), CIGNA Corporation (NYSE: CI) and Baxter International Inc. (NYSE: BAX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7653-100free.
CI: 100.00 (-1.02), VRX: 131.91 (-1.70), BAX: 70.90 (+2.45), CVS: 87.50 (+2.03), REGN: 368.51 (-3.88)
CVS Health Announces $10 Million Commitment to Stand Up To Cancer to Fund Innovative Cancer Research
PR Newswire - Mon Nov 03, 8:00AM CST
CVS/pharmacy, the retail division of CVS Health (NYSE: CVS), today announced an in-store fundraising campaign to help raise funds to support cancer research. Now through November 22, CVS/pharmacy customers will have the opportunity to support Stand Up To Cancer (SU2C) at the register in stores nationwide and online at www.cvs.com/SU2C. SU2C raises funds to accelerate the pace of cancer research to get new therapies to patients quickly and save lives. This campaign is part of CVS Health's three-year $10 million commitment to SU2C.
CVS: 87.50 (+2.03)
